Navigation Links
Endothelin in Medical News

FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension

...is marketed by United Therapeutics and its wholly-owned subsidiary, Lung Rx, Inc. Nearly all clinical experience has been on a background of an endothelin receptor antagonist or a phosphodiesterase type 5 inhibitor. Important Safety Information for TYVASO TYVASO is a prostacyclin vasodi...

Viagra Trial for Sickle Cell Lung Problems Halted

...ding to the institute, there are no current guidelines for treating pulmonary hypertension in people with sickle-cell disease, although drugs known as endothelin receptor blockers are sometimes used. The condition can lead to heart failure and death. A small pilot trial using Revatio and involving just 12 pe...

Blood flow in Alzheimer's disease

... Researchers have discovered that the enzyme, endothelin converting enzyme-2 (ECE-2), may cause the decrease in blood flow in the brain seen in Alzheimer's disease and contribute to progression of the diseas...

New Study Shows Long-Term Benefits for Patients with Pulmonary Arterial Hypertension

... Ambrisentan, approved for use in patients with PAH, is a selective oral endothelin receptor antagonist, which means it blocks the action of endothelin, a very...ty and fewer significant drug-to-drug interactions than other approved oral endothelin receptor antagonists. Without treatment the prognosis for patients wit...

Female Hormones Deter Salt-Sensitive Hypertension

...es to force the kidneys to get rid of excess salt. endothelin B (ETB) receptors, found in the blood vessels and ..."We know from other studies we have done that this endothelin B receptor is critical to keeping you from becomin...news release issued by the university. However, endothelin A (ETA) receptors counteract their siblings' work ...

24th Annual EAU Congress highlights many new developments

...tus of several novel agents in clinical trials either as single agents or in combination with cytotoxic chemotherapy, including the androgen receptor, endothelin receptor, and molecular chaperones. Dr. Smith from Boston (U.S.) is keen on presenting the exciting results of his trial (A randomized, double-blin...

Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success

...ytotoxic T lymphocyte-associated antigen 4 (CTLA4); dihydrofolate reductase (DHFR); DT-diaphorase (DTD); E2F; E2F1; endocytic lectin receptors (EELr); endothelin A (ETA) receptor (ETAr); ephrin B4 (EphB4); epithelial cell adhesion molecule (EpCam); estrogen receptor-alpha (Er-alpha); eukaryotic translation init...

Pollution Particles Impair Blood Vessel Function

...PM, but not ozone alone. In Ann Arbor, 50 adults were pre-treated with either the antioxidant vitamin C -- which blocks the vasoconstrictor hormone endothelin (bosentan) -- or placebo. Diastolic blood pressure increased between 2.5 and 4.0 mm/Hg during all exposures. However, blood pressure function was not ...

Blood vessels: The pied piper for growing nerve cells

...on of the arteries in mouse embryos confirmed that endothelin is found only in the external carotid. To confirm ...Gs had grown towards the beads. To be certain that endothelin directs nerve growth in the living animal, the researchers then looked in mice that had the endothelin gene removed. Sure enough, these mice had no nerve...

Lung damage in babies with congenital heart disease under study

... plenty of superoxides are produced that bind with nitric oxide and interfere with its effort to dilate blood vessels. Other things are just weird. endothelin typically works through the A receptor on the muscle cell and B receptor on the endothelial cell. In the animal model, endothelial cells have fewer of...
Endothelin in Medical Technology

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...ess and safety of imatinib mesylate 400 mg. The study participants had previously failed to improve after receiving standard therapy with prostanoids, endothelin antagonists or PDE-5 inhibitors. "There is a high unmet need for new treatments that address the underlying mechanisms of PAH," said David Epstein, ...

New Drug Application for Inhaled Treprostinil Submitted to the U.S. Food and Drug Administration

...ound therapy. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist, or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. The majority of patients were New York Heart Association (NYHA) Clas...

Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease

...ction of vasoactive compounds, such as endothelin. endothelin is produced by the endothelial cells and is essent...irst in a new class of treatments for PAH known as endothelin receptor antagonists. Tracleer(R) is a dual antago...l Hypertension (PAH) Tracleer(R) is an oral dual endothelin receptor antagonist, which is currently licensed f...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

...h severe PAH. The study population consisted of 235 patients who were optimized on an approved oral therapy for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist, or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. In addition to one of these oral therapies, patients were administer...

Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients

...y designed to incorporate two proven mechanisms -- endothelin (ETA) and angiotensin (AT1) receptor blockade -- i... alone, simultaneously blocking angiotensin II and endothelin 1 at their respective receptors, AT1 and ETA, may ... blood pressure-raising actions of angiotensin and endothelin when they bind to these receptors. About Pharmac...

Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)

...s well as reductions in systolic and diastolic blood pressure in non- hypertensive healthy subjects. PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DAR...

Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)

... well as reductions in systolic and diastolic blood pressure in non-hypertensive healthy volunteers. PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DAR...

Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development

...progressing well. The trial remains on schedule with results expected in the second quarter of 2008. PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and o...

Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)

...to see the first clear demonstration of the compound's potential efficacy in hypertensive patients." PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540, the first and only DAR...

Pharmacopeia Announces Third Quarter 2007 Financial Results

...clinical trial for PS433540, an unpartnered product candidate from its DARA program, that is both an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA). The trial was initiated less than one year after IND submission and approximately six months ahead of schedule. ...
Endothelin in Biological News

Will IVF work for a particular patient? The answer may be found in her blood

...tate. The molecular pathways that were most over-represented in this expression were concerned with angiogenesis (the growth of new blood vessels), endothelin signalling (blood vessel constriction), inflammation, oxidative stress (damage to cell structures), vascular endothelial growth factor (signalling pro...

Researchers may have found why women have an edge on salt-sensitive hypertension

...points to the need for gender studies on how these endothelin A, or ETA, receptors work in the blood vessels and...receptors have been considered the evil sibling of endothelin B, or ETB, receptors, which are believed to stimul..."We know from other studies we have done that this endothelin B receptor is critical to keeping you from becomin...

Mechanisms of cardiovascular disease and cancer give clues to new therapies

...r of cancers and cardiovascular disease, involving the pathway known as the endothelin axis. The endothelium is the thin layer of cells lining every blood vessel ...bling the tumour to spread, usually with fatal results. Understanding the endothelin axis and its role in both cancer and cardiovascular disease is now increasi...

Better understanding of blood vessel constrictor needed to harness its power for patients

... high blood pressure or heart failure, scientists must learn more about how endothelin functions naturally and in disease states, says a Medical College of Georgi...e target plays off another," says Dr. Ergul, who discussed novel aspects of endothelin receptor interaction during the 62nd High Blood Pressure Research Conferenc...

Blood pressure response to daily stress provides clues for better hypertension treatment

...handling. "We have animal model data that says the endothelin system normally functions to help your kidneys get...s Dr. Pollock. His studies have shown the kidney's endothelin B receptor plays a critical role in promoting excr...ence suggests it does. He'll also give the rats an endothelin antagonist, which blocks this hormone, and see if ...

Twin studies reveal genetic components leading to cardiac and kidney disease

... said O’Connor The endothelium secretes several hormones that are markers of how well it is functioning. Release of one of these markers, called endothelin (ET-1), is trigged by a gene that regulates catecholamines, chemical compounds produced in the adrenal gland that are released in reaction to stress. ...
Endothelin in Biological Technology

Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care

...biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in ...

GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.

...biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in ...

Pulmonary Hypertension Association Names Recipient of 2008 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care

...biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in ...

Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information

...y Arterial Hypertension (PAH) Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hy... have been prescribed Actelion's product Tracleer, an orally available dual endothelin receptor antagonist for patients with PAH with World Health Organization (W...

Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007

...ry Arterial Hypertension (PAH) Tracleer(R) (bosentan), the first oral dual endothelin receptor antagonist, is approved for the treatment of pulmonary arterial hy...scribed Actelion's product Tracleer(R) (bosentan), an orally available dual endothelin receptor antagonist for patients with World Health Organization (WHO) Class...

Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients

... A Proof Of Concept) Study of ZD4054 -- a specific endothelin A (ETA) receptor antagonist -- were delivered toda...ences: (1) James, M.D. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival i...(2) Morris, C.D. et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical ...
Other Tags
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... The ... by using a complex of the Cas9 nuclease with either a chimeric single guide ... (tracrRNA)). The ability of any given guide RNA (sgRNA or crRNA) to create a ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... According to an article published ... Governor Jerry Brown that aims to do away with grand juries in cases meant to ... Passed as a direct response to grand jury decisions in Ferguson and New York City ...
(Date:9/2/2015)... FL (PRWEB) , ... September 02, 2015 , ... ... Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by the ... Medicare patients – is likely to average approximately $71,000 or roughly 40% of ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an innovative ... its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone app ... A leader in health technology, RxNT was one of the first to build ...
(Date:9/2/2015)... ... 02, 2015 , ... Density measurement is used in many ... handling makes density measurements more efficient and error-free. The new METTLER TOLEDO video ... and the advantages compared to manual sample handling. , The Evolution of Density ...
Breaking Medicine News(10 mins):Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
(Date:8/26/2015)... 2015 The report "Multi-Factor Authentication (MFA) ... Application (Travel & Immigration, Government, Banking, Defense, Commercial Security, ... 2020", published by MarketsandMarkets, Multi-Factor Authentication Market is expected ... a CAGR of 17.7% between 2015 and 2020. ... igures spread through 169 P ages ...
(Date:8/20/2015)... , Aug. 20, 2015 The wearable ... that are active and healthy. However, wearable technology ... hospital environment to help improve diagnostic capabilities and ... from the Wearable Technologies Conference 2015 , ... applications for wearables in healthcare.    ...
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3
Other Contents